Methotrexate in psoriasis: revised guidelines (Q39514650)

12 September 2017

1 reference

title

Methotrexate in psoriasis: revised guidelines (English)

1 reference

12 September 2017

1 reference

H H Roenigk

1

1 reference

12 September 2017

R Auerbach

series ordinal

2

1 reference

12 September 2017

H I Maibach

series ordinal

3

1 reference

12 September 2017

G D Weinstein

series ordinal

4

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 July 1988

1 reference

Journal of the American Academy of Dermatology

12 September 2017

1 reference

12 September 2017

19

1 reference

12 September 2017

1 Pt 1

1 reference

12 September 2017

145-156

1 reference

Methotrexate in psoriasis. A brief review of indications, usage, and complications of methotrexate therapy

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

The use of methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate guidelines--revised

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

1 reference

7 January 2021

Commentary: three decades of folic acid antagonists in dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Reappraisal of the use of methotrexate in rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Cirrhosis Associated With Methotrexate Treatment of Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long-term methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Changes in liver histology during methotrexate therapy of psoriasis correlated to the concentration of methotrexate and folate in erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate therapy in rheumatoid arthritis: 15 years experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Ultrasound and radionuclide scans--poor indicators of liver damage in patients treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Effects of methotrexate on the liver in psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Hepatotoxicity after long-term methotrexate therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate maintenance therapy and liver damage in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate-induced liver cirrhosis. A follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Letter: Renal function in methotrexate treated psoriatics

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Renal function and the rate of disappearance of methotrexate from serum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Clinical pharmacology of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Low-dose methotrexate kinetics in arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Megaloblastic anaemia and methotrexate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Intestinal function and methotrexate absorption in psoriatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Impact of methotrexate therapy on the folate status of psoriatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

The pharmacology and clinical use of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Prolongation and enhancement of serum methotrexate concentrations by probenecid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate and etretinate as concurrent therapies in severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate and etretinate as concurrent therapies in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Risk and prognostic factors in trophoblastic neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

No Increase in Second Tumors after Cytotoxic Chemotherapy for Gestational Trophoblastic Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Studies of human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Chromosome Studies in Patients Treated With Azathioprine and Amethopterin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate-induced congenital malformations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Congenital anomalies among children born of mothers receiving chemotherapy for gestational trophoblastic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Pregnancies after chemotherapy of trophoblastic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Cytogenetic Evaluation of Methotrexate-Treated Psoriatic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Reproductive performance of women successfully treated for gestational trophoblastic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Pulmonary complications following methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Pulmonary function in patients on long-term, low-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate-induced pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Cryptococcosis associated with low-dose methotrexate for arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Methotrexate and the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Small-vessel vasculitis and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

The co-occurrence of Reiter's syndrome and acquired immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Treatment of generalized pustular psoriasis with methotrexate and colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Familial juvenile generalized pustular psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis. Evaluation and prognosis based on the study of 104 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2980237-8

7 January 2021

10.1016/S0190-9622(88)80237-8

Identifiers

DOI

0 references

1 reference